Roflumilast + Pioglitazone + Placebo + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohapatitis
Conditions
Nonalcoholic Steatohapatitis
Trial Timeline
Jun 1, 2013 → Sep 1, 2014
NCT ID
NCT01703260About Roflumilast + Pioglitazone + Placebo + Placebo
Roflumilast + Pioglitazone + Placebo + Placebo is a phase 2 stage product being developed by AstraZeneca for Nonalcoholic Steatohapatitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01703260. Target conditions include Nonalcoholic Steatohapatitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01703260 | Phase 2 | Terminated |
Competing Products
20 competing products in Nonalcoholic Steatohapatitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK2809 + Placebos | Viking Therapeutics | Phase 2 | 47 |
| TERN-501 + TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-201 | Terns Pharmaceuticals | Phase 1 | 30 |
| Lanifibranor | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo + Empagliflozin | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo | Inventiva | Phase 3 | 72 |
| Colesevelam Hcl | Daiichi Sankyo | Phase 2 | 52 |
| Tirzepatide + Placebo | Eli Lilly | Phase 2 | 52 |
| AZD2693 | AstraZeneca | Phase 2 | 52 |
| MK-3655 + Placebo | Merck | Phase 2 | 52 |
| Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL | Merck | Phase 2 | 52 |
| SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mg | Gilead Sciences | Phase 3 | 76 |
| Seladelpar + Placebos | Gilead Sciences | Phase 2 | 51 |
| Cilofexor | Gilead Sciences | Phase 1 | 32 |
| Firsocostat + Fenofibrate | Gilead Sciences | Phase 1 | 32 |
| GS-9674 + Placebo to match GS-9674 | Gilead Sciences | Phase 2 | 51 |
| SEL + FIR + CILO + Placebo to match FIR + Placebo to match CILO + Placebo to match SEL | Gilead Sciences | Phase 2 | 51 |
| GS-9450 + GS-9450 Placebo | Gilead Sciences | Phase 2 | 51 |
| Semaglutide + Firsocostat + Cilofexor | Gilead Sciences | Phase 2 | 51 |